ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 9.05
(-1.63%)
CNY 9.05
(-1.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 40.15 Million CNY | 134.89% |
| 2022 | -115.09 Million CNY | -44.64% |
| 2021 | -79.57 Million CNY | 74.75% |
| 2020 | -315.11 Million CNY | -666.37% |
| 2019 | -41.11 Million CNY | -177.78% |
| 2018 | -14.8 Million CNY | -151.36% |
| 2017 | 28.81 Million CNY | 21.55% |
| 2016 | 23.7 Million CNY | -23.2% |
| 2015 | 30.86 Million CNY | -40.23% |
| 2014 | 51.64 Million CNY | 25.23% |
| 2013 | 41.24 Million CNY | 64.24% |
| 2012 | 25.11 Million CNY | -38.69% |
| 2011 | 40.95 Million CNY | -14.66% |
| 2010 | 47.98 Million CNY | 26.04% |
| 2009 | 38.07 Million CNY | 170.04% |
| 2008 | 14.09 Million CNY | 0.0% |
| 2007 | 14.09 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 20.35 Million CNY | -11.18% |
| 2024 Q1 | 18.86 Million CNY | -59.92% |
| 2024 Q2 | 22.91 Million CNY | 21.45% |
| 2023 Q4 | 47.07 Million CNY | 195.78% |
| 2023 FY | 40.15 Million CNY | 134.89% |
| 2023 Q2 | -20.22 Million CNY | -674.18% |
| 2023 Q3 | 15.91 Million CNY | 178.69% |
| 2023 Q1 | -2.61 Million CNY | 97.32% |
| 2022 Q1 | -5.31 Million CNY | 93.79% |
| 2022 Q4 | -97.6 Million CNY | -3723.0% |
| 2022 FY | -115.09 Million CNY | -44.64% |
| 2022 Q3 | 2.69 Million CNY | 118.12% |
| 2022 Q2 | -14.87 Million CNY | -179.93% |
| 2021 FY | -79.57 Million CNY | 74.75% |
| 2021 Q1 | -2.14 Million CNY | 98.82% |
| 2021 Q2 | 498.09 Thousand CNY | 123.18% |
| 2021 Q3 | 7.66 Million CNY | 1439.87% |
| 2021 Q4 | -85.59 Million CNY | -1215.93% |
| 2020 Q4 | -182.41 Million CNY | -279.3% |
| 2020 FY | -315.11 Million CNY | -666.37% |
| 2020 Q1 | -54.09 Million CNY | 0.74% |
| 2020 Q2 | -30.51 Million CNY | 43.6% |
| 2020 Q3 | -48.09 Million CNY | -57.61% |
| 2019 FY | -41.11 Million CNY | -177.78% |
| 2019 Q4 | -54.49 Million CNY | -964.7% |
| 2019 Q3 | -5.11 Million CNY | -137.81% |
| 2019 Q2 | 13.53 Million CNY | 172.74% |
| 2019 Q1 | 4.96 Million CNY | 115.53% |
| 2018 Q4 | -31.95 Million CNY | -1047.02% |
| 2018 Q3 | -2.78 Million CNY | -118.75% |
| 2018 FY | -14.8 Million CNY | -151.36% |
| 2018 Q1 | 5.07 Million CNY | 586.12% |
| 2018 Q2 | 14.86 Million CNY | 192.59% |
| 2017 Q3 | -324.98 Thousand CNY | -101.8% |
| 2017 Q4 | 740.3 Thousand CNY | 327.8% |
| 2017 FY | 28.81 Million CNY | 21.55% |
| 2017 Q1 | 10.33 Million CNY | 197.41% |
| 2017 Q2 | 18.06 Million CNY | 74.81% |
| 2016 FY | 23.7 Million CNY | -23.2% |
| 2016 Q4 | -10.61 Million CNY | -265.16% |
| 2016 Q3 | 6.42 Million CNY | -64.47% |
| 2016 Q2 | 18.08 Million CNY | 84.35% |
| 2016 Q1 | 9.8 Million CNY | 252.07% |
| 2015 Q4 | -6.45 Million CNY | -146.92% |
| 2015 FY | 30.86 Million CNY | -40.23% |
| 2015 Q1 | 12.06 Million CNY | 41.52% |
| 2015 Q2 | 11.5 Million CNY | -4.62% |
| 2015 Q3 | 13.74 Million CNY | 19.49% |
| 2014 Q3 | 16.8 Million CNY | 13.12% |
| 2014 FY | 51.64 Million CNY | 25.23% |
| 2014 Q1 | 11.46 Million CNY | 14.31% |
| 2014 Q2 | 14.85 Million CNY | 29.54% |
| 2014 Q4 | 8.52 Million CNY | -49.26% |
| 2013 Q4 | 10.03 Million CNY | 7.53% |
| 2013 FY | 41.24 Million CNY | 64.24% |
| 2013 Q1 | 7.76 Million CNY | 916.92% |
| 2013 Q2 | 14.11 Million CNY | 81.7% |
| 2013 Q3 | 9.32 Million CNY | -33.91% |
| 2012 Q4 | 763.87 Thousand CNY | -88.78% |
| 2012 FY | 25.11 Million CNY | -38.69% |
| 2012 Q2 | 11.13 Million CNY | 73.72% |
| 2012 Q3 | 6.8 Million CNY | -38.87% |
| 2012 Q1 | 6.4 Million CNY | 105.5% |
| 2011 Q2 | 16.37 Million CNY | 41.63% |
| 2011 Q1 | 11.56 Million CNY | -44.11% |
| 2011 FY | 40.95 Million CNY | -14.66% |
| 2011 Q4 | 3.11 Million CNY | -68.5% |
| 2011 Q3 | 9.9 Million CNY | -39.53% |
| 2010 Q4 | 20.68 Million CNY | 218.34% |
| 2010 Q3 | 6.49 Million CNY | 0.0% |
| 2010 FY | 47.98 Million CNY | 26.04% |
| 2009 FY | 38.07 Million CNY | 170.04% |
| 2008 FY | 14.09 Million CNY | 0.0% |
| 2007 FY | 14.09 Million CNY | 0.0% |